Director
IRCCS Ca' Granda Maggiore Hospital Foundation, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milano, Italy; Università degli Studi di Milano, Department of Pathophysiology and Transplantation, Milano, Italy
Milano, Lombardia, Italy
FLORA PEYVANDI is professor of Internal Medicine at the University of Milan, Italy and director of the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center of the Milan Policlinic Hospital, Italy.
Her research started with molecular and biochemical characterization of coagulation disorders aiming at the development of novel treatment for the affected patients. Her research continued with the understanding of the microvascular dysfunctions in order to implement/develop and standardize innovative diagnostic and therapeutic strategies.
Since many years, Dr. Peyvandi has been participating in clinical, educational and research activities of different European and International scientific societies and patients’ organizations. She is currently the President of the International Society of Thrombosis and Haemostasis and Past-President of the Executive Committee of the European Association for Haemophilia and Allied Disorders. She also serves as advisor on the European Agency of Medicine and on the Technical Health Committee of the Italian Ministry of Health. Her clinical, teaching and research experience combined with her life in different countries, led her to familiarize with patient management, scientific projects and educational systems of different parts of the world.
Saturday, June 24, 2023
08:05 – 08:15 ET
Sunday, June 25, 2023
10:45 – 11:00 ET
Sunday, June 25, 2023
14:45 – 15:00 ET
Sunday, June 25, 2023
15:15 – 15:30 ET
Sunday, June 25, 2023
15:15 – 15:30 ET
SSC 12.2 - Need for standardisation - What parameters are relevant for gene therapy of haemophilia?
Sunday, June 25, 2023
16:35 – 16:50 ET
PB0027 - Assessing genetic risk factors for early-onset coronary artery disease in Iranians
Sunday, June 25, 2023
18:30 – 19:30 ET
PB0189 - Knowledge and attitudes of haemophilic patients toward gene therapy
Sunday, June 25, 2023
18:30 – 19:30 ET
Sunday, June 25, 2023
18:30 – 19:30 ET
Sunday, June 25, 2023
18:30 – 19:30 ET
PB0321 - Prospective evaluation of the HemosIL AcuStar ADAMTS13 Activity Assay
Sunday, June 25, 2023
18:30 – 19:30 ET
Sunday, June 25, 2023
18:30 – 19:30 ET
Sunday, June 25, 2023
18:30 – 19:30 ET
SOA 14.2 - The Role of Non-Replacement Therapies in Bleeding Disorders Other Than Hemophilia
Monday, June 26, 2023
08:25 – 08:50 ET
Monday, June 26, 2023
18:30 – 19:30 ET
PB0663 - Risk Factors for Atherosclerosis in Patients with Hemophilia
Monday, June 26, 2023
18:30 – 19:30 ET
PB0667 - Development and clinical utility of anti-emicizumab antibody detection assays
Monday, June 26, 2023
18:30 – 19:30 ET
Monday, June 26, 2023
18:30 – 19:30 ET
Tuesday, June 27, 2023
11:00 – 11:15 ET
Tuesday, June 27, 2023
15:00 – 15:15 ET
OC 60.4 - Joint damage in patients affected by Von Willebrand disease: a single-center experience
Tuesday, June 27, 2023
15:30 – 15:45 ET
Tuesday, June 27, 2023
18:30 – 19:30 ET
Wednesday, June 28, 2023
10:45 – 11:00 ET